ArticleFrontiers in neurology
Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ublituximab is a glycoengineered monoclonal antibody that effectively reduces multiple sclerosis (MS) relapses but carries a significant risk of infusion-related reactions (IRRs), which is relatively higher than that reported for some other anti-CD20 agents. This study aims to characterize real-world IRRs associated with ublituximab and describe premedication practices across participating centers. Methods: This multicenter retrospective study included ublituximab-treated MS patients identified from existing medical records (a convenience sample) at MS centers across the United States. Data on demographics, MS phenotype, premedication regimens, and IRRs were collected. Variables were summarized, and Fisher's exact test was used to compare the occurrence and timing of IRRs across baseline and premedication categories. Also, associations between premedication strategies and IRRs were assessed by logistic regression. We conducted statistical analyses using JAMOVI (v2.5). Results: Among 89 patients with multiple sclerosis (PwMS) treated with ublituximab, 34.8% ( Conclusion: Approximately one-third (34.8%) of ublituximab-treated patients experienced IRRs, with varied timing and symptom patterns. No independent predictors of IRRs were identified. Importantly, all IRRs observed in this study were mild to moderate, suggesting that ublituximab infusions were generally well tolerated in this real-world cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.